EDIT - Editas Medicine - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

EDIT is currently covered by 16 analysts with an average price target of $3.1. This is a potential upside of $1.78 (134.85%) from yesterday's end of day stock price of $1.32.

Editas Medicine's activity chart (see below) currently has 106 price targets and 118 ratings on display. The stock rating distribution of EDIT is 51.11% BUY, 44.44% HOLD and 4.44% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 48% with an average time for these price targets to be met of 134.84 days.

Highest price target for EDIT is $12, Lowest price target is $1, average price target is $7.55.

Most recent stock forecast was given by BRIAN CHENG from JPMORGAN on 16-Dec-2024. First documented stock forecast 29-Feb-2016.

Currently out of the existing stock ratings of EDIT, 23 are a BUY (51.11%), 20 are a HOLD (44.44%), 2 are a SELL (4.44%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

$9

3 months 29 days ago
(16-Dec-2024)

2/2 (100%)

$0.14 (1.58%)

9

Buy

$5

$3.7 (284.62%)

$7

3 months 29 days ago
(16-Dec-2024)

2/5 (40%)

$3.52 (237.84%)

7

$3

$1.7 (130.77%)

$5

4 months 1 days ago
(13-Dec-2024)

8/12 (66.67%)

$1.56 (108.33%)

200

Hold

$3

$1.7 (130.77%)

$11

4 months 1 days ago
(13-Dec-2024)

4/8 (50%)

$1.56 (108.33%)

38

Hold

$3

$1.7 (130.77%)

$7

4 months 1 days ago
(13-Dec-2024)

3/8 (37.5%)

$1.56 (108.33%)

56

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is EDIT (Editas Medicine) average time for price targets to be met?

On average it took 134.84 days on average for the stock forecasts to be realized with a an average price target met ratio 48

Which analyst has the current highest performing score on EDIT (Editas Medicine) with a proven track record?

STEVEN SEEDHOUSE

Which analyst has the most public recommendations on EDIT (Editas Medicine)?

Steven Seedhouse works at RAYMOND JAMES and has 5 price targets and 3 ratings on EDIT

Which analyst is the currently most bullish on EDIT (Editas Medicine)?

Cory Kasimov with highest potential upside - $21.82

Which analyst is the currently most reserved on EDIT (Editas Medicine)?

Greg Harrison with lowest potential downside - -$0.3

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?